Pan Xu

Pan Xu

Auto-generated profile, based on publicly available information

Pan Xu

Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2017 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SSSokrates Stein
Sokrates Stein
VLVera Lemos
Vera Lemos
PXPan Xu
Pan Xu
HDHadrien Demagny
Hadrien Demagny
Xu WangXu Wang
Xu Wang
KSKristina Schoonjans
Kristina Schoonjans
Hepatic steatosis is caused by metabolic imbalances that could be explained in part by an increase in de novo lipogenesis that results from increased sterol element binding protein 1 (SREBP-1) activity. The nuclear receptor liver receptor homolog 1 (LRH-1) is an important regulator of intermediary metabolism in the liver, but its role in regulating lipogenesis is not well understood. Here, we have assessed the contribution of LRH-1 SUMOylation to the development of nonalcoholic fatty liver disease (NAFLD). Mice expressing a SUMOylation-defective mutant of LRH-1 (LRH-1 K289R mice) developed NAFLD and early signs of nonalcoholic steatohepatitis (NASH) when challenged with a lipogenic, high-fat, high-sucrose diet. Moreover, we observed that the LRH-1 K289R mutation induced the expression of oxysterol binding protein-like 3 (OSBPL3), enhanced SREBP-1 processing, and promoted de novo lipogenesis. Mechanistically, we demonstrated that ectopic expression of OSBPL3 facilitates SREBP-1 processing in WT mice, while silencing hepatic Osbpl3 reverses the lipogenic phenotype of LRH-1 K289R mice. These findings suggest that compromised SUMOylation of LRH-1 promotes the development of NAFLD under lipogenic conditions through regulation of OSBPL3.

1 October 2014 in Cell Metabolism
Verified
Journal Article
Closed access
SSSokrates Stein
Sokrates Stein
MOMaaike H. Oosterveer
Maaike H. Oosterveer
CMChikage Mataki
Chikage Mataki
PXPan Xu
Pan Xu
VLVera Lemos
Vera Lemos
KSKristina Schoonjans
Kristina Schoonjans

1 June 2016 in Genes & Development
Verified
Journal Article
Open access
PDF file
PXPan Xu
Pan Xu
MOMaaike H. Oosterveer
Maaike H. Oosterveer
SSSokrates Stein
Sokrates Stein
HDHadrien Demagny
Hadrien Demagny
Dongryeol RyuDongryeol Ryu
Dongryeol Ryu
KSKristina Schoonjans
Kristina Schoonjans
Various tumors develop addiction to glutamine to support uncontrolled cell proliferation. Here we identify the nuclear receptor liver receptor homolog 1 (LRH-1) as a key regulator in the process of hepatic tumorigenesis through the coordination of a noncanonical glutamine pathway that is reliant on the mitochondrial and cytosolic transaminases glutamate pyruvate transaminase 2 (GPT2) and glutamate oxaloacetate transaminase 1 (GOT1), which fuel anabolic metabolism. In particular, we show that gain and loss of function of hepatic LRH-1 modulate the expression and activity of mitochondrial glutaminase 2 (GLS2), the first and rate-limiting step of this pathway. Acute and chronic deletion of hepatic LRH-1 blunts the deamination of glutamine and reduces glutamine-dependent anaplerosis. The robust reduction in glutaminolysis and the limiting availability of α-ketoglutarate in turn inhibit mTORC1 signaling to eventually block cell growth and proliferation. Collectively, these studies highlight the importance of LRH-1 in coordinating glutamine-induced metabolism and signaling to promote hepatocellular carcinogenesis.

14 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PXPan Xu
Pan Xu
EEElhaseen Elamin
Elhaseen Elamin
MEMontserrat Elizalde
Montserrat Elizalde
PBPaul P. H. A. Bours
Paul P. H. A. Bours
MPMarieke J. Pierik
Marieke J. Pierik
DJDaisy M. A. E. Jonkers
Daisy M. A. E. Jonkers
Intestinal epithelial barrier is affected by multiple factors, such as tumour necrosis factor-α (TNF-α). Plasma concentration of TNF-α is higher in patients with Crohn’s disease (CD) than healthy controls (HC) and correlates positively with disease activity. This study aimed to determine the effect of plasma from active, inactive CD patients on intestinal barrier function and to investigate the underlying mechanism. Plasma samples were collected from CD patients and HC. 3D Caco-2 cysts were treated with plasma or TNF-α, with or without pre-incubation of adalimumab (a monoclonal antibody that antagonizes TNF-α) or JNK inhibitor SP600125. The results demonstrated that exposure of the cysts to plasma from CD patients resulted in enhanced paracellular permeability in a disease activity-dependent manner. Compared to HC, active CD plasma decreased ZO-1 and OCCLUDIN expression on mRNA and protein levels, and led to an increased JNK phosphorylation. Pre-incubation with adalimumab or SP600125 ameliorated TJ disruption and barrier dysfunction induced by plasma from CD patients. These results indicate that plasma from CD patients is able to induce epithelial barrier disruption, in part through TNF-α induced TJs modulation. The data also demonstrate an involvement of MAPK pathway, in particular the JNK isoform, in CD patient plasma-induced barrier dysfunction.

5 December 2017 in Gut
Verified
Journal Article
Closed access
PDF file
PXPan Xu
Pan Xu
HBHeike Becker
Heike Becker
MEMontserrat Elizalde
Montserrat Elizalde
AMAd Masclee
Ad Masclee
DJDaisy Jonkers
Daisy Jonkers

18 June 2022 in International Journal of Hydrogen Energy
Verified
Journal Article
Closed access
PXPan Xu
Pan Xu
JWJian Wen
Jian Wen
SWSimin Wang
Simin Wang
GLGang Lei
Gang Lei
Yanzhong LiYanzhong Li
Yanzhong Li